CENTESSA PHARMACEUTICALS PLC Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-03-31..
Quick ratio
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 36.57M USD | Liabilities, Current |
| Cash and equivalents | 62.43M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | (m) | $36.57M | $62.43M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $42.94M | $61.30M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $29.12M | $50.81M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $29.69M | $44.24M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $24.20M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $58.00M | $383.22M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $26.41M | $395.03M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $26.75M | $127.37M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $27.43M | $118.22M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $39.38M | $128.03M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $34.95M | $171.50M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $33.87M | $145.22M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $29.69M | $259.99M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $38.34M | $393.64M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $38.19M | $444.84M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $33.57M | $484.16M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $27.19M | $544.47M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $24.64M | $595.08M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $29.14M | $578.82M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $24.18M | $613.76M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $8.62M | $7.23M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.